The successful Phase III clinical trial of a dry-eye drug in Japan has earned Inspire Pharmaceuticals (Nasdaq: ISPH) a $1.25 million milestone payment.

Santen Pharmaceuticals licensed Inspire’s “diquafosol” and is planning to seek marketing approval to sell the drug in June.

Santen also has license, development and supply agreements for the drug in China, South Korea, Singapore and other Asian markets.